Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation”

2 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 2 of 2 results

Large-scale testing (Phase 3)Study completedNCT02740335
What this trial is testing

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Who this might be right for
Significant Bleeding Risk
Octapharma 208
Post-approval studies (Phase 4)Study completedNCT03064035
What this trial is testing

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

Who this might be right for
Acute Bleeding on Long-Term Anticoagulation TherapyHemorrhageSignificant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)+1 more
HealthPartners Institute 79